Home Ingredients Glabridin (Licorice Isoflavone)
CardiovascularMetabolic HealthHair, Skin & NailsAntioxidant

Glabridin (Licorice Isoflavone)

Glycyrrhiza glabra L. — isolated isoflavonoid
Evidence Level
Limited
3 Clinical Trials
7 Documented Benefits
2/5 Evidence Score

Glabridin is an isoflavonoid specific to Glycyrrhiza glabra L. (licorice root) — distinct from glycyrrhizin (the licorice compound that causes pseudoaldosteronism at high doses). The most-studied licorice flavonoid, with multi-target activity across lipid, glucose, and skin pigmentation pathways. A 6-month trial at 250 mg/day reported plasma LDL oxidation reduced 20% — an atheroprotective mechanism distinct from cholesterol-lowering. Smaller trials in type 2 diabetes and metabolic syndrome at 300 mg/day showed reductions in cholesterol, glycated hemoglobin, and visceral fat. Skin applications use the topical route — glabridin inhibits tyrosinase 16x more potently than hydroquinone in vitro and reduces UV-induced hyperpigmentation in clinical studies. Critical limitation: only about 7.5% oral bioavailability — branded delivery systems like Glavonoid® (MCT oil emulsion from Kaneka) are preferable for systemic effects. The honest framing: promising multi-target compound with small-trial evidence; oral bioavailability is the practical bottleneck, and trial sample sizes (10-50 subjects) limit definitive conclusions.

Studied Dose LDL oxidation: 250 mg/day for 6 months. Type 2 diabetes and metabolic syndrome: 300 mg/day for 12 weeks. Critical: oral bioavailability is only ~7.5% — Glavonoid® MCT-oil delivery is preferred over purified glabridin for systemic effects.
Active Compound Glabridin (isoflavonoid specific to Glycyrrhiza glabra) — located in cork layer + decayed roots. Stability influenced by temperature, pH, light, humidity. Best stored dry, dark, low oxygen, neutral pH

Benefits

LDL oxidation reduction (6-month trial)

A pivotal 6-month trial in 19 healthy subjects at 250 mg/day showed plasma LDL oxidation decreased 20%. Atheroprotective mechanism distinct from cholesterol-lowering — addresses the oxidative-modification step in atherogenesis rather than circulating cholesterol levels themselves.

Supported by Trial 1

Type 2 diabetes multi-domain effects

A 12-week trial in 10 type 2 diabetes patients at 300 mg/day showed reductions in total cholesterol, LDL-cholesterol, glycated hemoglobin, immunoreactive glucagon, and body fat composition. Multi-target metabolic effects in a small sample. Sample size limits definitive conclusions but the multi-domain pattern is consistent with AMPK activation.

Supported by Trial 2

Metabolic syndrome 12-week trial

A 12-week trial in 50 metabolic syndrome patients at 300 mg/day normalized body weight, BMI, visceral fat, and HDL-cholesterol. Larger sample size than the type 2 diabetes trial; multi-domain metabolic syndrome endpoints showed broad normalization.

Supported by Trial 3

Skin lightening and hyperpigmentation

Glabridin shows 16 times more potent tyrosinase inhibition than hydroquinone in vitro. A clinical study in 18 subjects showed a hydroquinone-free formula containing glabridin significantly reduced UV-induced hyperpigmentation versus both negative control and 4% hydroquinone cream. Multiple Asian cosmeceutical research applications.

Supported by Trial 1, Trial 2

Anti-atherogenic activity

Glabridin is the most abundant and potent antioxidant among the licorice constituents tested for LDL oxidation inhibition. The ring-B 2'-hydroxyl is critical to activity per structure-activity studies — clean mechanistic rationale supporting the clinical LDL oxidation findings.

Supported by Trial 1

Anti-inflammatory effects

NF-κB pathway suppression and reduced inflammatory cytokines in cellular and animal models. Mechanistic complement to the metabolic and atheroprotective effects observed in human trials.

Supported by Trial 2, Trial 1

Antimicrobial activity (original discovery)

Glabridin was first isolated during a search for antimicrobial agents in licorice root via bioassay-directed fractionation. The original discovery rationale; antimicrobial applications less explored in clinical research than the metabolic and skin uses.

Supported by Trial 1, Trial 2

Mechanism of action

1

LDL oxidation inhibition (primary atheroprotective mechanism)

Glabridin directly inhibits LDL oxidation — the lipid peroxidation step that initiates foam cell formation in atherogenesis. Ring-B 2'-hydroxyl is critical to activity per structure-activity studies. Distinct from cholesterol-lowering: addresses oxidative modification rather than circulating cholesterol levels.

2

Tyrosinase inhibition (skin lightening)

16× more potent than hydroquinone in vitro. Tyrosinase is the rate-limiting enzyme in melanin biosynthesis — inhibition reduces UV-induced hyperpigmentation. The clinical-evidence-supported mechanism for the cosmeceutical application.

3

AMPK activation (metabolic mechanism)

Glabridin activates AMP-activated protein kinase (AMPK) — the central metabolic energy sensor. Downstream effects include increased fatty acid oxidation and GLUT4 translocation supporting glucose uptake. Mechanism for the multi-target metabolic effects in Hattori 2019 and Panda 2017.

4

NF-κB anti-inflammatory pathway suppression

Suppression of NF-κB signaling reduces inflammatory cytokine production. Anti-inflammatory mechanism complementing the metabolic effects.

5

Mild estrogen receptor binding (phytoestrogenic)

Mild phytoestrogenic activity via estrogen receptor binding. Caution applies in hormone-sensitive conditions (estrogen-receptor-positive breast cancer, endometriosis, etc.).

6

Low oral bioavailability (~7.5%) — delivery limitation

Critical pharmacokinetic limitation: oral bioavailability is only about 7.5%. Glavonoid® MCT-oil delivery system from Kaneka substantially enhances bioavailability vs purified glabridin — practical preference for systemic effects. Topical formulations bypass this limitation for skin-lightening applications.

Clinical trials

1
Carmeli 2009 — Glabridin LDL Oxidation 6-Month Trial (PIVOTAL)

Carmeli E & Fogelman Y 2009 — 6-month trial in 19 healthy subjects at 250 mg/day glabridin. Plasma LDL oxidation decreased 20%. First clinical demonstration of glabridin-driven LDL oxidation reduction in humans — atheroprotective mechanism distinct from cholesterol-lowering.

2
Hattori 2019 — Glabridin Type 2 Diabetes 12-Week Trial

Hattori K 2019 — 12-week trial in 10 type 2 diabetes patients at 300 mg/day. Reduced total cholesterol, LDL-cholesterol, glycated hemoglobin, immunoreactive glucagon, and body fat composition. Multi-target metabolic effects in small sample.

3
Panda 2017 — Glabridin Metabolic Syndrome 12-Week Trial

Panda et al. 2017 — 12-week trial in 50 metabolic syndrome patients at 300 mg/day. Normalized body weight, BMI, visceral fat, and HDL-cholesterol. Larger sample size; multi-domain metabolic syndrome endpoints.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated — flavonoid fraction (NO glycyrrhizin pseudoaldosteronism risk).
Mild GI upset (rare).
Allergic reactions in licorice-sensitive individuals (rare).
Pregnancy/lactation: limited data; precautionary avoidance.
Estrogen-sensitive conditions: theoretical mild phytoestrogenic effects — caution.
Long-term safety: 6-month Carmeli trial supportive at 250 mg/day.
DELIVERY LIMITATION: ~7.5% bioavailability — branded delivery systems (Glavonoid® MCT) preferred.

Important Drug interactions

Statins: COMPATIBLE; complementary cholesterol effects.
Antidiabetic medications: theoretical compatible/additive glucose effects (Hattori 2019 evidence) — monitor blood glucose.
Antihypertensives: theoretical mild effects.
Anticoagulants: minimal interactions documented.
Most medications: well-tolerated combination profile.
Hormone-sensitive treatments (tamoxifen, etc.): caution due to mild phytoestrogenic activity.
Cytochrome P450 substrates: theoretical interactions (lower with flavonoid fraction vs glycyrrhizin).

More Cardiovascular Ingredients

Cardiovascular
Niacin
Niacin, or vitamin B3, is a vital nutrient that supports energy production by serving as a…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cardiovascular
Potassium
Potassium is the most abundant intracellular cation in the human body and an essential min…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…

Explore Other Ingredients

Antioxidant
Lutein
Lutein is a yellow carotenoid antioxidant that plays a key role in eye health, particularl…
Hair, Skin & Nails
Hyaluronic Acid
Hyaluronic acid is a naturally occurring substance in the body, primarily found in connect…
Immune Support
Vitamin C
Vitamin C, also known as ascorbic acid, is a water-soluble vitamin commonly used in supple…

Frequently asked questions about Glabridin (Licorice Isoflavone)

What is Glabridin (Licorice Isoflavone)?

Glabridin is an isoflavonoid specific to Glycyrrhiza glabra L.

What does Glabridin (Licorice Isoflavone) do?

Glabridin directly inhibits LDL oxidation — the lipid peroxidation step that initiates foam cell formation in atherogenesis. Ring-B 2'-hydroxyl is critical to activity per structure-activity studies. In clinical research, Glabridin (Licorice Isoflavone) has been studied for ldl oxidation reduction (6-month trial), type 2 diabetes multi-domain effects, metabolic syndrome 12-week trial.

Who should take Glabridin (Licorice Isoflavone)?

Glabridin (Licorice Isoflavone) may be most relevant for people interested in cardiovascular, metabolic health, hair, skin & nails. It has been clinically studied for ldl oxidation reduction (6-month trial), type 2 diabetes multi-domain effects, metabolic syndrome 12-week trial. As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does Glabridin (Licorice Isoflavone) take to work?

Most clinical trial effects appear over weeks of consistent use; individual response varies. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take Glabridin (Licorice Isoflavone)?

For cardiovascular or metabolic goals, Glabridin (Licorice Isoflavone) is typically taken with meals to support absorption and reduce GI sensitivity. Effects on biomarkers (cholesterol, blood pressure, blood sugar) build over 8-12+ weeks of consistent daily use. Always check product labeling and follow personalized guidance from your healthcare provider.

Is Glabridin (Licorice Isoflavone) worth taking?

Glabridin (Licorice Isoflavone) has limited clinical evidence (Evidence Level 2/5 on NutraSmarts) — preliminary research suggests potential benefit, but more rigorous trials are needed. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. Glabridin (Licorice Isoflavone) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of Glabridin (Licorice Isoflavone)?

The clinically studied dose for Glabridin (Licorice Isoflavone) is LDL oxidation: 250 mg/day for 6 months. Type 2 diabetes and metabolic syndrome: 300 mg/day for 12 weeks. Critical: oral bioavailability is only ~7.5% — Glavonoid® MCT-oil delivery is preferred over purified glabridin for systemic effects.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Glabridin (Licorice Isoflavone) used for?

Glabridin (Licorice Isoflavone) is studied for ldl oxidation reduction (6-month trial), type 2 diabetes multi-domain effects, metabolic syndrome 12-week trial. A pivotal 6-month trial in 19 healthy subjects at 250 mg/day showed plasma LDL oxidation decreased 20%.